BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - BridgeBio Pharma reported preliminary unaudited Q4 and Full Year 2025 net product revenue of $146.0 million and $362.4 million respectively, indicating strong commercial performance for its product Attruby (acoramidis) [1] - Attruby is becoming the preferred therapy for newly diagnosed ATTR-CM patients, with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, driven by its differentiated clinical data and increasing real-world confidence [1] - The company announced a new TTR amyloid depleter antibody program aimed at exploring the potential for ATTR-CM disease reversal, with clinical advancement expected between 2027 and 2028 [1] - Interim analysis from the FORTIFY Phase 3 study of BBP-418 in LGMD2I/R9 showed significant benefits, leading the FDA to recommend a traditional full approval pathway, with an NDA submission planned for the first half of 2026 [1] - A rapid increase in the diagnosis of ADH1 has been noted, with over 1,700 unique patients identified since October 2023, and an NDA submission for encaleret based on CALIBRATE trial results is anticipated in the first half of 2026 [1] - The initiation of the RECLAIM-HP Phase 3 trial for encaleret in chronic hypoparathyroidism is scheduled for summer 2026 following a successful End of Phase 2 interaction with the FDA [1] - The PROPEL 3 Phase 3 study of infigratinib for children with achondroplasia has achieved LPLV, with topline results expected by the end of Q1 2026 [1] - As of December 31, 2025, the company had approximately $587.5 million in cash, cash equivalents, and marketable securities, positioning it well to support the acceleration of Attruby and potentially launch three additional medicines globally [1] Company Overview - BridgeBio Pharma is a biopharmaceutical company focused on genetic diseases, founded in 2015, with a commitment to delivering transformative medicines quickly and effectively [2][7] - The company operates on a decentralized model, aiming to double the number of patients served by the end of 2026 [2]